Lilly purchases integrated cellular screening system from Amersham Biosciences

Published: 6-Nov-2003

Eli Lilly and Company has purchased an integrated suite of cellular screening technology and licenses from UK-based Amersham Biosciences to help in the identification of potential therapeutics in its drug discovery programme.


Eli Lilly and Company has purchased an integrated suite of cellular screening technology and licenses from UK-based Amersham Biosciences to help in the identification of potential therapeutics in its drug discovery programme.

In addition to the purchase of an IN Cell Analyzer 3000 high-throughput sub-cellular imaging system, Lilly has signed an agreement with Amersham for rights to Aequorea Victoria Green Fluorescent Protein (GFP). Furthermore, Lilly has secured rights to operate under BioImage's Redistribution patent portfolio for monitoring intracellular signalling pathways, including protein translocation.

'Lilly's decision to utilise GFP and Redistribution technology together with the IN Cell Analyzer 3000 reflects the trend in the pharmaceutical industry towards generating biological information earlier in the drug development process to speed up the time to market,' said Mike Evans, vice president marketing and strategy, discovery systems at Amersham Biosciences.

  

You may also like